Foghorn Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing a sharp rise in collaboration revenue and a reduction in accumulated deficit compared to year-end 2025.

Key Highlights

  • Collaboration revenue of $83.543 million was recorded for the three months ended September 30, 2026, compared to $8.153 million in the same period of 2025, according to the filing.
  • Nine-month collaboration revenue reached $102.882 million for the period ended September 30, 2026, versus $21.662 million for the nine months ended September 30, 2025.
  • Accumulated deficit narrowed to $601.383 million at September 30, 2026, down from $632.467 million at December 31, 2025.
  • Total stockholders' deficit improved to $(14.084) million at September 30, 2026, compared to $(108.500) million at December 31, 2025.
  • Restructuring costs of $2.272 million were recorded in the three months ended September 30, 2026, with no comparable charge in the prior-year period.
  • Shares outstanding were 59,962,650 as of October 30, 2026, up from 56,657,329 at December 31, 2025.
  • Total assets were $190.952 million at September 30, 2026, versus $198.103 million at December 31, 2025.

Foghorn Therapeutics Reports Q3 2026 Financial Results and Collaboration Revenue Surge

Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, reported collaboration revenue of $83.543 million for the three months ended September 30, 2026, a significant increase from $8.153 million in the third quarter of 2025, according to the Form 10-Q filing. For the nine months ended September 30, 2026, collaboration revenue totaled $102.882 million, compared to $21.662 million for the same period in 2025.

Total operating expenses for the three months ended September 30, 2026 were $26.904 million, the filing disclosed, compared to $26.654 million in the third quarter of 2025. Research and development expenses were $18.836 million for the quarter, down from $20.002 million a year earlier. General and administrative expenses were $5.796 million, compared to $6.652 million in the prior-year quarter. The filing also reported restructuring costs of $2.272 million in the third quarter of 2026, with no such costs recorded in the comparable 2025 period. For the nine months ended September 30, 2026, research and development expenses totaled $55.618 million and general and administrative expenses totaled $18.731 million.

On the balance sheet, the company reported cash and cash equivalents of $80.302 million and marketable securities of $75.920 million at September 30, 2026. Deferred revenue, including both current and long-term portions, stood at $18.874 million and $127.398 million, respectively, at September 30, 2026, down from $43.192 million and $205.962 million at December 31, 2025. Total liabilities decreased to $205.036 million from $306.603 million at year-end 2025. The company reported a total stockholders' deficit of $(14.084) million at September 30, 2026, an improvement from $(108.500) million at December 31, 2025. The filing notes that forward-looking statements are subject to risks and uncertainties described in the company's cautionary language.

What Was Disclosed

Foghorn Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, reporting a large increase in collaboration revenue, restructuring costs of $2.272 million, a reduced accumulated deficit, and balance sheet changes including lower deferred revenue and total liabilities compared to December 31, 2025.